During the last years cancer immunotherapy has emerged as a safe and effective alternative to cancers that do not respond to classical treatments including those types with high aggressiveness. New immune modulators like cytokines, blockers of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and PD-1(programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) interaction or adoptive cell therapy have been developed and approved to treat solid and haematological carcinomas. In these scenarios, cytotoxic lymphocytes (CL), mainly cytotoxic T (Tc) and Natural Killer (NK) cells are the ultimate responsible of killing the cancer cells and eradicate the tumour. Extensive studies have been developed on how Tc and NK cells get activated and recognise the cancer cell. In contrast few studies have been focused on the effector molecules employed by CL to kill cancer cells during both cancer immunosurveillance and immunotherapy. During the next sections the two main pathways involved in CL-mediated tumour cell death, granule exocytosis (perforin and granzymes) and death ligands, will be briefly introduced followed by a critical discussion of the molecules involved in cell death during cancer immunosurveillance and immunotherapy. Recent experimental evidences indicate that perforin and granzymes of CLs can activate non-apoptotic pathways of cell death overcoming cellular resistance to traditional treatments. In addition, neither all granzymes present cytotoxic potential nor death ligands always contribute to cancer elimination. Here the consequences of apoptosis versus other modalities of cell death for an effective treatment of cancer by modulating the patient immune system will be also briefly discussed.
Introduction
The ultimate goal of the immune response during cancer immunosurveillance and immunotherapy is the elimination of the cancer cells.
Cytotoxic lymphocytes (CL), cytotoxic T (Tc) and Natural Killer (NK) cells, are the main players in this process. Other cell types like macrophages, mast cells or dendritic cells may also kill transformed cells albeit its specific role and the molecules used for this aim are not clear. Although triggered via distinct receptors, Tc and NK cells employ the same basic mechanisms to destroy their target cells: one is elicited by granule exocytosis (i.e. perforin -PRF1-and granzymes -GZM-), the other via the death ligand/death receptor system ( Fig. 1) {Russell, 2002 #158}.
Both effector pathways trigger programmed intracellular events in target cells, leading in most cases to apoptotic cell death {Bolitho, 2007 #333; Fulda, 2015 #3006}. Accordingly, it has been generally assumed that therapies targeting direct or indirectly CL would activate those pathways to ultimately kill the cancer cell.
However, looking in the detail at the molecular level one realises that it is not so clear which molecules are the actual responsible of executing cancer cells during both immunosurveillance and immunotherapy. Notably in some cases these mechanisms may be different during the native response against cell transformation (i.e. cancer immunosurveillance) and during the elimination of cancer cells by the pharmacological manipulation of the immune response (see Table 1 ). Most importantly, under circumstances where apoptosis is blocked by pathogen-derived or endogenous intracellular inhibitors (i.e. IAPs or Bcl-2 family members) {Gibson, 4 apoptosis is not always required for CL-mediated killing {Voskoboinik, 2015 Ewen, 2011 Pardo, 2009 #385; Chowdhury, 2008 These questions, which may seem trivial for the elimination of cancer cells, are important in the context of recent findings indicating that the subsequent response of the immune system against dying cells greatly depends on the way how cells die i.e. if cell death is immunogenic or not {Zitvogel, 2010 #2893; Casares, 2005 #2990}. other cytoplasmic granule-associated molecules like the human-specific protein granulysin {Krensky, 2009 #2927} have been described, though their biological functions during cancer immunity and immunotherapy have not been elucidated {Pardo, 2009 #385; Bovenschen, 2010 Voskoboinik, 2015 In most cases PRF1 act as a vehicle for GZMs delivery into the cytosol of the target cell by a mechanism that seems to be dependent on its ability to form pores in membranes {Voskoboinik, 2006 #307}. Paradoxically, this event, one of the most critical steps controlling the elimination of cancer cells, is still a matter of intense debate and it is only now beginning to be clarified. It seems that, as suggested almost 30 years ago, PRF1 forms pores in the plasma membrane to allow GZMs access to the target cell cytosol, although the nature of the pore is not clear {Lopez, 2013 #2930;
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Metkar, 2011 #2931}. However it is still unknown if the alternative models proposed ( receptor-or clathrin-mediated GZM endocytosis and release from endosomes by coendocytosed PRF1), operate under some circumstances depending on the target cell {Pipkin, 2007 #1067}. In addition, when using susceptible target cells or in specific situations where GZMs would not be expressed or would be inhibited, PRF1 per se may be able to kill target cells by inducing cell lyses. This hypothesis is supported by experiments showing that rat basophil leukemia cells transiently transfected with PRF1 cDNA lyse Jurkat cells {Voskoboinik, 2004 #2994}. On this context changes in the lipid composition of the plasma membrane in cancer cells may influence its response (either as GZM-delivery or as lytic agent) to PRF1, modulating the sensitivity of cells to CL and immunotherapy {Lehmann, 2000 #2932; Antia, 1992 #2933}.
Once released in the cytosol GZMs would execute the target cells by cleaving critical intracellular substrates controlling cell death and survival. Substrates of GZMs also include viral and cellular proteins crucial for virus replication {Andrade, 2010 #2959} as well as extracellular matrix proteins controlling vascular integrity, inflammation and skin aging {Parkinson, 2014 Hiebert, 2012 Hendel, 2010 #2709} but this will not be treated in this article. However, which GZMs activate cell death and the features of dying cells are only now beginning to be clarified in physiological models.
Who is who during cell death induced by CL in cancer immunosurveillance and immunotherapy?

Cancer immunosurveillance
Most of the evidence gained from studies using mouse in vivo models indicate that PRF1 is a key factor for NK-and Tc -mediated control of both transplanted syngeneic tumours as well as during chemical carcinogenesis (table 1 and {Bolitho, 2007 #333; van den Broek, 1996 #211; Pardo, 2002 #386; Davis, 2001 #36}) . This also applies to control of cancer metastasis {Smyth, 1999 Bolitho, 2007 #333}. Indeed, early as well as more recent studies indicate that Tc and NK cells from which may mask the anti-tumour potential of CL-associated GzmB.
Although these discrepancies have not been clarified yet it has been argued that other GZMs might compensate the absence of GZMA and GZMB, meanwhile PRF1 deficiency would inactivate the anti-tumour function of all GZMs. However, deficiency in other GZMs like GZMM {Pao, 2005 #467} does not increase the susceptibility to implanted syngeneic cancer cell lines including lymphoma and melanoma. We still do not know the phenotype of mice deficient in GZMK but it should be expected that their susceptibility to tumours is not increased since its cytotoxic potential in vitro is very low {Joeckel, 2011 #2853}. Here it may be possible that, in the absence of GZMs, PRF1 per se would eliminate cancer cells by inducing cell lysis in a similar way as the complement membrane attack complex as previously suggested {Voskoboinik, 2006 #307} (Fig. 2) .
In some cases cell death induced by PRF1 deficient CL can be restored at longer incubation times in specific tumour cell types that presents sensitivity to FasL , suggesting that this death ligand may also contribute to tumour immunosurveillance in vivo {Kagi, 1994 #91; Lowin, 1994 #232; Screpanti, 2005 In contrast to PRF1 and Fas, there have not been described any human mutations in TRAIL or TRAIL-R that correlate with a higher predisposition to cancer development.
Cancer Immunotherapy
In contrast to cancer immunosurveillance the involvement of PRF1 and GZMs during cancer immunotherapy has not been explored in deep and the available results are not clear. The potent immunodominant Tc cell epitope, lymphocytic choriomeningitis virus (LCMV) peptide gp33, has been widely used as a model tumour antigen to analyse the elimination of cancer cells by activating virus specific Tc cell responses. Using this model, we have found that prevention and elimination of syngeneic grafted cancer cells lines of diverse origin depends of the presence of PRF1 and is not affected by FasL deficiency (manuscript under preparation).
. Several works have pursued to reveal the role of PRF1 and Death Ligands in the elimination of cancer cells by immune modulators used in clinics like immunostimulatory antibodies or cytokines (Table 1) . However the results are difficult to interpret since generally different tumour models have been employed. A summary of the results obtained using immune modulators is depicted in figure 1 and table 1. Table 1 Regarding cytokine therapy most studies have been focused in cytokines that predominantly activate NK/NKT cell-mediated responses. The elimination of melanoma and sarcoma murine cell lines by IL-12 {Song, 2000 Sin, 2012 #2944} or IL-15 {Liu, 2012 #2947} was dependent on PRF1 expression. PRF1 was also required to control melanoma tumour metastasis by IL-12 {Schultz, 1999 Kodama, 1999 . In contrast PRF1 deficiency did not affect IL-12 and αGalCer (alpha-galactosylceramide)-mediated control of liver metastasis using the RENCA renal carcinoma model. In this case metastasis was inhibited by anti-TRAIL therapy {Smyth, 2001 #2969}. Another study confirmed that PRF1 deficiency did not affect the anti-metastatic activity of αGalCer in the B16 melanoma model {Hayakawa, 2001 #2989}. Finally, it was shown that the anti-tumour effect of IL-12 against melanoma cells in mice was dependent on PRF1 {Hashimoto, 1999 #2941}. In contrast the same study showed that IL-18 activity was dependent on FasL and independent of PRF1.
As shown in
As previously suggested it seems that the effect of IL12 during cancer immunotherapy is model dependent {Smyth, 2000 #3001}.
Another approach used to treat cancer is the so called adoptive cell transfer A conclusion that can be reached from these studies is that in some types of cancer the cell death executors involved in cancer immunosurveillance maybe different from those activated by immunotherapy. This hypothesis is strongly supported when comparing studies analysing immunosurveillance and immunotherapy in similar tumour models (table 1) 
Apoptotic and non-apoptotic pathways activated by granule exocytosis
It has been assumed that the final consequence of the concerted action of PRF1 and GZMs is the induction of cell death, by a mechanism known as apoptosis (Fig. 2) {Voskoboinik, 2015 #2958}. However, this overreaching conclusion mainly obtained from in vitro models using purified GZMs delivered with a great variety of agents, may not be true. In contrast recent evidences indicate that neither all GZMs present cytotoxic potential nor the mechanism of cell death activated by CL is always apoptosis (Fig. 2) Here we have found that Tc cells require GZMB-mediated cell death to prevent development of tumours at long term (Manuscript under preparation).
However, cell death induced by CL through GZMB is not always apoptotic in nature. This fact is particularly evident when target cells in which apoptotic pathways are blocked are employed. It has been found that Tc cells use PRF1 and GZMB to kill cells in which both the intrinsic mitochondrial pathway and caspases are blocked {Pardo, 2008 #390}, highlighting the potential benefits of immunotherapy to treat cancer cells that do not respond to conventional therapy {Gibson, 2015 #3008; Fulda, 2015 #3006}. We have recently confirmed in humans that allogeneic activated NK cells expressing GZMB eliminate haematological cancer cells in which apoptosis is blocked by p53 mutation, over-expression of Bcl-X L even in the presence of caspase inhibitors {Sanchez-Martinez, 2015 #2953}. However, under these circumstances the phenotype of dying cells is not apoptotic and PS translocation did not preceded membrane permeability. The characteristics of this type of cell death as well as its consequences for the immune system are currently being explored.
In conclusion cell death induced by CL in the absence of GZMB or in target cells in which apoptosis is blocked may not be enough to amplify the anti-tumour immune response and establish anti-tumour memory that prevents future tumour relapse. 
Other modalities of cell death
Death ligands
It is known from long time ago that death receptor ligation leads to caspasedependent apoptotic cell death (Fig. 2) {Fulda, 2015 #3006}. However, the mechanism of cell death shifts from apoptosis to necroptosis in the presence of caspase inhibitors {Vandenabeele, 2010 #2986} (Fig. 2) . The molecular mechanism of death receptor-induced necroptosis, that involves the kinases RIP1 (receptorinteracting protein 1) and RIP3, has been described recently 
Concluding remarks
CL (Tc and NK cells) are the main effector cells executing transformed cells during cancer immunosurveillance and immunotherapy. However, the experimental evidences suggest that the molecular mechanisms involved in immunosurveillance are not always the same as those in immunotherapy. PRF1 and GZMB is the most potent pathway used by CL to kill cancer cells, overcoming anti-apoptotic mutations including p53 deletion/mutation, over-expression or down-regulation of members of the Bcl-2 family and caspase inhibition. Thus, under these circumstances, apoptosis is not required for CL-mediated target cell killing. Notably, in the absence of GZMB (i.e. gene mutation or expression of endogenous inhibitors), PRF1 per se could induce cell lysis in susceptible target cells. In contrast, TRAIL seems to be involved in the control of metastasis and FasL could compensate in some instances PRF1 deficiency.
Originally the main effector pathways of CL, PRF1/GZMs and death ligands, were thought to act exclusively by inducing apoptotic cell death on transformed cells.
Recent experimental evidences indicate that during the interaction between CL and tumour cells, non-apoptotic cell death pathways, inflammation induced by some granzymes and death ligands and proliferative effects of death ligands may unexpectedly contribute to cancer progression rather than control. A better understanding on how CL actually kill cancer cells during immunotherapy will help to predict patient responses and to select the best protocols to get activated CL that efficiently kill tumour cells without inducing other undesirable effects. Granzyme A regulates the production of pro-inflammatory cytokines (IL-1β) by a mechanism dependent on caspase-1. The contribution of the inflammasome platforms to this process is suggested although not proven yet. In in vitro experiments using purified proteins, it has been described that granzyme A is also able to cleave a protein known as NADH dehydrogenase ubiquinone iron-sulfur protein 3 (NDUFS3) inducing mitochondrial depolarization (↓ ΔΨM) and reactive oxygen species (ROS) production. ROS generation in turn induce DNA damage and the subsequent activation of DNA-repairing mechanisms, among them, the SET complex which translocates from the ER (endoplasmic reticulum) to the nucleus. In the nucleus, granzyme A would cleave some SET-complex proteins such as SET , pp32 and Ape1 (apurinic/apyrimidinic endonuclease 1) releasing the nuclease NM23H1 (nonmetastatic clone 23 human 1). In turn, released NM23H1 would induce DNA damage triggering cell death.
It has been described that purified granzymes C, F, H, K and M are able to induce cell death in the presence of perforin by activating diverse intracellular pathways, although the physiological relevance of this ability is questioned {Pardo, 2009 #385; Joeckel, 2014 #2950; Voskoboinik, 2015 #2958}. In addition, it has also been reported that granzymes K and M can also regulate the production of proinflammatory cytokines.
Induction of cell death of tumour cells by CL induces phosphatidylserine
translocation of calreticulin and maybe other danger signals like ATP (adenosine triphosphate). These events are necessary for a proper activation of the immune system against the dying tumour cells.
Regarding death ligands, FasL (Fas ligand) and TRAIL (TNF-related apoptosis inducing ligand) bind to their respective death receptors Fas for FasL and TRAIL-R1/2 for TRAIL, promoting receptor oligomerisation. Consequently, the oligomerised death receptors recruit the adaptor protein Fas-associated death domain (FADD) through homotypic interaction between their death domains. The death effector domain of FADD in turn binds procaspase-8, allowing its trans-activation. Active caspase-8 triggers two different apoptotic pathways depending on the cell type. Active caspase-8 cleaves procaspase-3, which is able to degrade distinct substrates leading to cell death by apoptosis and also the BH3-only pro-apoptotic protein Bid, generating tBid, which, as described above, activate the mitochondrial apoptotic pathway.
Apoptosis through the death receptor pathway can be inhibited at different levels.
Cellular FLICE inhibitory protein (c-FLIP) can compete with caspase-8 for the binding to FADD inhibiting caspase-8 activation. In some circumstances in which caspase-8 is inactive, TRAIL-Rs and possibly also Fas ligation can recruit receptor interacting protein (RIP)1 and RIP3, forming a complex named necrosome which phosphorylates MLKL (mixed lineage kinase domain-like protein) promoting its oligomerisation. Then, MLKL inserts into and permeabilises plasma membrane leading to necrotic cell death. Finally, TRAIL can also trigger proliferation and survival signals if apoptosis is blocked. TRAIL-Rs also can recruit RIP upon TRAIL binding, leading to a secondary complex formation containing TNF receptorassociated factor 2 (TRAF2) and TNF receptor type 1-associated death domain (TRADD). RIP1 can then promote the activation of the transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and of mitogenactivated protein kinases (MAPK) and Akt kinase (protein kinase B), promoting survival signals.
